Why Pfizer Stock Just Popped

Key Points

• Pfizer will buy Metsera for at least $47.50 per share.

• Pfizer could end up paying closer to $70 per share.

• Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates.

• 10 stocks we like better than Pfizer ›

Pfizer (NYSE: PFE), the one-time COVID vaccine hero turned Ozempic craze zero, is marching higher Monday after announcing it will try to recover from its danuglipron setback by buying another drug company with weight loss dreams.

As of 12:25 p.m. ET, Pfizer stock is up 2.1 %.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Image source: Getty Images.

Pfizer buys Metsera

Pharmaceutical giant Pfizer intends to purchase smaller Metsera (NASDAQ: MTSR), which has "four highly differentiated clinical-stage incretin and amylin programs." These include:

• MET-097i, an injectable GLP-1 weight loss drug in Phase 2 clinical trials
• A Phase 1 injectable GLP-1 drug called MET-233i
• Two preclinical trial oral GLP-1 candidates

Pfizer intends to pay $47.50 per share up front to acquire all of Metsera's stock, plus potentially $22.50 per share more in milestone payments as Metsera's drug candidates progress through trials to the marketplace. When all's said and done, Pfizer could end up paying as much as $7.2 billion to get back in the GLP-1 weight loss game.

Is Pfizer stock a buy?

This is not a cheap price, and Pfizer's not in the best position to pay it. Valued at more than $136 billion in market capitalization, Pfizer sports a reasonable price-to-free-cash-flow (FCF) ratio, but its $50 billion in net debt (largely taken on through prior ill-considered acquisitions) inflates its enterprise value-to-FCF ratio to 15.

Ordinarily, that would be a fine valuation, except most analysts expect Pfizer's profits to shrink, not expand, in future years. The company's making a risky and expensive bet here in hopes it can win entry into the GLP-1 space and start growing again... eventually.

Success isn't certain, however. If Metsera's drugs don't pan out, Pfizer could end up paying twice what Metsera stock was worth Friday, and get little or nothing out of it.

Should you invest $1,000 in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $661,694!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,082,963!*

Now, it’s worth noting Stock Advisor’s total average return is 1,067% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 22, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.